vs
Side-by-side financial comparison of ASTRONICS CORP (ATRO) and CorMedix Inc. (CRMD). Click either name above to swap in a different company.
ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $128.6M, roughly 1.9× CorMedix Inc.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $15.8M).
Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
ATRO vs CRMD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.1M | $128.6M |
| Net Profit | — | — |
| Gross Margin | 33.3% | 83.4% |
| Operating Margin | 14.8% | 46.0% |
| Net Margin | — | — |
| Revenue YoY | 15.1% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.82 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $240.1M | $128.6M | ||
| Q3 25 | $211.4M | $104.3M | ||
| Q2 25 | $204.7M | $39.7M | ||
| Q1 25 | $205.9M | $39.1M | ||
| Q4 24 | $208.5M | — | ||
| Q3 24 | $203.7M | — | ||
| Q2 24 | $198.1M | — | ||
| Q1 24 | $185.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-11.1M | $108.6M | ||
| Q2 25 | $1.3M | $19.8M | ||
| Q1 25 | $9.5M | $20.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-11.7M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | 33.3% | 83.4% | ||
| Q3 25 | 30.5% | 89.3% | ||
| Q2 25 | 25.8% | 95.3% | ||
| Q1 25 | 29.5% | 95.9% | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 27.1% | — | ||
| Q2 24 | 28.0% | — | ||
| Q1 24 | 25.7% | — |
| Q4 25 | 14.8% | 46.0% | ||
| Q3 25 | 10.9% | 49.2% | ||
| Q2 25 | 2.3% | 49.2% | ||
| Q1 25 | 6.4% | 51.5% | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | -5.2% | 104.1% | ||
| Q2 25 | 0.6% | 49.9% | ||
| Q1 25 | 4.6% | 52.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | -1.7% | — |
| Q4 25 | $0.82 | $0.20 | ||
| Q3 25 | $-0.31 | $1.26 | ||
| Q2 25 | $0.04 | $0.28 | ||
| Q1 25 | $0.26 | $0.30 | ||
| Q4 24 | $-0.07 | — | ||
| Q3 24 | $-0.34 | — | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $148.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $140.1M | $405.3M |
| Total Assets | $706.7M | $826.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $148.5M | ||
| Q3 25 | $13.5M | $55.7M | ||
| Q2 25 | $13.5M | $190.7M | ||
| Q1 25 | $24.8M | $77.5M | ||
| Q4 24 | $9.3M | — | ||
| Q3 24 | $5.2M | — | ||
| Q2 24 | $2.9M | — | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $140.1M | $405.3M | ||
| Q3 25 | $108.9M | $374.1M | ||
| Q2 25 | $271.6M | $220.6M | ||
| Q1 25 | $266.8M | $114.9M | ||
| Q4 24 | $256.1M | — | ||
| Q3 24 | $249.2M | — | ||
| Q2 24 | $257.9M | — | ||
| Q1 24 | $251.7M | — |
| Q4 25 | $706.7M | $826.1M | ||
| Q3 25 | $682.2M | $750.9M | ||
| Q2 25 | $646.7M | $252.6M | ||
| Q1 25 | $662.2M | $149.6M | ||
| Q4 24 | $648.8M | — | ||
| Q3 24 | $651.6M | — | ||
| Q2 24 | $644.9M | — | ||
| Q1 24 | $630.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.6M | $94.5M |
| Free Cash FlowOCF − Capex | $15.8M | $92.7M |
| FCF MarginFCF / Revenue | 6.6% | 72.1% |
| Capex IntensityCapex / Revenue | 4.9% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $172.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.6M | $94.5M | ||
| Q3 25 | $34.2M | $30.9M | ||
| Q2 25 | $-7.6M | $30.0M | ||
| Q1 25 | $20.6M | $19.7M | ||
| Q4 24 | $26.4M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-6.3M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | $15.8M | $92.7M | ||
| Q3 25 | $21.0M | $30.4M | ||
| Q2 25 | $-12.2M | $30.0M | ||
| Q1 25 | $18.5M | $19.7M | ||
| Q4 24 | $23.2M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $-8.1M | — | ||
| Q1 24 | $439.0K | — |
| Q4 25 | 6.6% | 72.1% | ||
| Q3 25 | 9.9% | 29.1% | ||
| Q2 25 | -6.0% | 75.4% | ||
| Q1 25 | 9.0% | 50.5% | ||
| Q4 24 | 11.1% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -4.1% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 4.9% | 1.3% | ||
| Q3 25 | 6.2% | 0.5% | ||
| Q2 25 | 2.2% | 0.1% | ||
| Q1 25 | 1.0% | 0.0% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.28× | ||
| Q2 25 | -5.81× | 1.51× | ||
| Q1 25 | 2.17× | 0.96× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.08× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRO
| Product Line Electrical Power And Motion | $113.8M | 47% |
| Product Line Avionics | $32.0M | 13% |
| Military Aircraft | $28.0M | 12% |
| General Aviation | $22.3M | 9% |
| Government And Defense | $20.5M | 9% |
| Product Line Systems Certification | $13.2M | 6% |
| Product Line Structures | $3.7M | 2% |
| Product Line Other | $2.3M | 1% |
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
